News und Analysen
![Guidance leads the market for these stocks; 1 raises, 1 lowers: https://www.marketbeat.com/logos/articles/med_20231106115927_chart-abbv-1162023ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBem5MYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ca00c01365083cf758de1cbddc6c791afe797131/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231106115927_chart-abbv-1162023ver001.png?locale=de)
Guidance leads the market for these stocks; 1 raises, 1 lowers
Because earnings guidance is a company's best effort to forecast its earnings, it is a leading cause of share price movement. However, simply raising or lowering guidance is not enough to move a
![J&J stock down as business unit mulls talc-related bankruptcy: https://www.marketbeat.com/logos/articles/med_20231031061438_jj-stock-down-as-business-unit-mulls-talc-related.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNm5DYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3b4e4009717b3b79d8a100afaaf4d0d826bac35f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231031061438_jj-stock-down-as-business-unit-mulls-talc-related.jpg?locale=de)
J&J stock down as business unit mulls talc-related bankruptcy
Shares of Johnson & Johnson (NYSE: JNJ) slid 4.84% lower the week ending October 27, as the company’s subsidiary LTL Management is facing a raft of lawsuits pertaining to talc in its baby powder.
![High-yield, deep-value AbbVie fell off the patent cliff and lived: https://www.marketbeat.com/logos/articles/med_20231027084929_high-yield-deep-value-abbvie-fell-off-the-patent-c.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM20vYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b84a2b98c39ccf1f28473ac7ff22aea7f1088448/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231027084929_high-yield-deep-value-abbvie-fell-off-the-patent-c.jpg?locale=de)
High-yield, deep-value AbbVie fell off the patent cliff and lived
Shares of AbbVie Inc. (NYSE: ABBV) have been under pressure for nearly two years because of mounting fears about the patent cliff. The patent cliff impacted the company’s results but has done
![The Value Deepens for Medtech Stocks: Reversal Imminent: https://www.marketbeat.com/logos/articles/med_20231023085140_chart-bax-10232023ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFM1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d1bd08a09883dcaf0726883a8123849ccee19e62/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231023085140_chart-bax-10232023ver001.png?locale=de)
The Value Deepens for Medtech Stocks: Reversal Imminent
Results from Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad
![Oversold and Overextended, Abbott Laboratories is a Great Buy: https://www.marketbeat.com/logos/articles/med_20231018080123_chart-abt-10182023ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmkwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4953dbca1ea9cdfdd288777a28824f138700e5aa/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231018080123_chart-abt-10182023ver001.png?locale=de)
Oversold and Overextended, Abbott Laboratories is a Great Buy
Abbott Laboratories (NYSE: ABT) share price has trended lower for nearly 2 years, but that trend is over. The impact of COVID on sales and the post-COVID letdown were cause enough for the market
![Walgreens Boots Alliance: Value or Value Trap?: https://www.marketbeat.com/logos/articles/med_20231012112832_chart-wba-10122023ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL091YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1220828144310370c5f4fd7115ffffe05f2e8bc9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231012112832_chart-wba-10122023ver001.png?locale=de)
Walgreens Boots Alliance: Value or Value Trap?
Walgreens Boots Alliance (NASDAQ: WBA) shares are down significantly over the past two years and may fall further. The company's turnaround efforts are slowly taking hold, and the impact of
![Prescriptions for Portfolio Health: 3 Resilient Healthcare Stocks: https://www.marketbeat.com/logos/articles/med_20231012063005_prescriptions-for-portfolio-health-3-resilient-hea.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODJ0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c5944d0ceb3b1a4bbf66b78e943d0a54c27f63ca/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231012063005_prescriptions-for-portfolio-health-3-resilient-hea.jpg?locale=de)
Prescriptions for Portfolio Health: 3 Resilient Healthcare Stocks
Over the last several months, many sectors, industries, and the overall market have come under pressure and experienced significant outflows and waves of selling.
During this period, over the
![Healthcare Giant Outperforms: A Healthy Dose of Market Resilience: https://www.marketbeat.com/logos/articles/med_20231009082049_healthcare-giant-outperforms-a-healthy-dose-of-mar.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlNwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1db26caf824eaff1d051d8ccef9cd9b6189ce20e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231009082049_healthcare-giant-outperforms-a-healthy-dose-of-mar.jpg?locale=de)
Healthcare Giant Outperforms: A Healthy Dose of Market Resilience
Over the last month, the overall market has experienced significant selling amid increased uncertainty. The S&P 500 ETF Trust (NYSE: SPY) has traded almost 5.5% lower in that period, and wherever
![3 Undervalued Healthcare Stocks to Watch as Sector Struggles: https://www.marketbeat.com/logos/articles/med_20231006072717_3-undervalued-healthcare-stocks-to-watch-as-sector.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHVvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f900c3e8f374021907c2083400d74525a5cdca9c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231006072717_3-undervalued-healthcare-stocks-to-watch-as-sector.jpg?locale=de)
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.40% in the past three months, and down 4.67% year-to-date.
With the current sector-wide downturn, it’s not surprising that
![Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?: https://www.marketbeat.com/logos/articles/med_20230928074106_can-undervalued-healthcare-stocks-add-yield-to-you.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzZlYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2d4bfb628f94a8120ac95affc214c0ccd49eb6c8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230928074106_can-undervalued-healthcare-stocks-add-yield-to-you.jpg?locale=de)
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
If you had to guess the largest S&P company outside of big tech stocks or Berkshire Hathaway Inc. (NYSE: BRK.B), would you guess a healthcare stock?
Health insurer UnitedHealth Group Inc. (NYSE:
![2 Stocks to Benefit from the Aging Population: https://www.marketbeat.com/logos/articles/med_20230924134458_chart-abt2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWFiYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--63ce225a495fe67b2a99fd35bc4529febeef2582/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230924134458_chart-abt2.jpg?locale=de)
2 Stocks to Benefit from the Aging Population
While the direction of the stock markets is unpredictable, the growth of the aging population is entirely predictable. Along with an aging population come additional healthcare, beauty and
![Are Gene Therapy Stocks The Market's Next Big Winners?: https://www.marketbeat.com/logos/articles/med_20230925062932_are-gene-therapy-stocks-the-markets-next-big-winne.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUdiYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--32c516995736b99a5271f36da910e4b57cb21478/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230925062932_are-gene-therapy-stocks-the-markets-next-big-winne.jpg?locale=de)
Are Gene Therapy Stocks The Market's Next Big Winners?
It’s not often that you see a company whose main product comes with a price tag of over $2 million, but that’s the case with biotechs BioMarin Pharmaceutical (NASDAQ: BMRN) and Sarepta
![Argenx's 28% Surge & Promising Product Propel Investor Confidence: https://www.marketbeat.com/logos/articles/med_20230924200315_argenxs-28-surge-promising-product-propel-investor.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL21hYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--31f8233da06ba46411c0d97269db60cda1f70e3f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230924200315_argenxs-28-surge-promising-product-propel-investor.jpg?locale=de)
Argenx's 28% Surge & Promising Product Propel Investor Confidence
If you want to get an isolated view of a constructive base taking shape in a strong stock, take a look at the Argenix SE (NASDAQ: ARGX) chart.
The stock gapped up nearly 28% on July 17, after
![Flee to Healthcare Stocks if Recession Rears its Head?: https://www.marketbeat.com/logos/articles/med_20230919053331_flee-to-healthcare-stocks-if-recession-rears-its-h.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOCtXYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--995bc34015550a0096b18438d978b2e9bd10ebaa/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230919053331_flee-to-healthcare-stocks-if-recession-rears-its-h.jpg?locale=de)
Flee to Healthcare Stocks if Recession Rears its Head?
If you’re looking for a sector that’s on sale, look to healthcare. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.50% in the past month, lagging the S&P 500.
The top
![Can These 3 Healthcare Dividend Stocks Deliver Income Growth?: https://www.marketbeat.com/logos/articles/med_20230918072814_can-these-3-healthcare-dividend-stocks-deliver-inc.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHFVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--67d41303862f14e269a379e27c68cb80634f63c3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230918072814_can-these-3-healthcare-dividend-stocks-deliver-inc.jpg?locale=de)
Can These 3 Healthcare Dividend Stocks Deliver Income Growth?
The healthcare industry presents a fertile shopping ground for undervalued dividend stocks. S&P 500 components Pfizer Inc. (NYSE: PFE), Medtronic plc (NYSE: MDT) and Gilead Sciences Inc. (NASDAQ:
![High Yield, Low Beta Stocks to Buy for the Next Market Meltdown: https://www.marketbeat.com/logos/articles/med_20230911124127_chart-abbv-9112023ver002.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTZOYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e0516abb6b5fe55510c527d5f311ace04dfa8efa/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230911124127_chart-abbv-9112023ver002.png?locale=de)
High Yield, Low Beta Stocks to Buy for the Next Market Meltdown
The market's fear indicator, the VIX index, is bobbing along at long-term lows and gives little indication of a looming correction, but investors should assume one is brewing. The index is down at
![Insiders Are Buying These 2 Stocks: https://www.marketbeat.com/logos/articles/med_20230908091904_insiders-are-buying-these-2-stocks.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUNMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--768bab93aeee2c9f6c643badc725cdf8b7b90784/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230908091904_insiders-are-buying-these-2-stocks.jpg?locale=de)
Insiders Are Buying These 2 Stocks
Understanding insider buying is crucial for savvy investors looking to make informed decisions in the stock market. Insider buying occurs when company insiders, such as executives or directors,
![How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?: https://www.marketbeat.com/logos/articles/med_20230831130002_how-much-pain-will-lower-medicare-prices-cause-for.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHlFYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a203f85407482410fd828e6fc10da35ade3d1c00/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230831130002_how-much-pain-will-lower-medicare-prices-cause-for.jpg?locale=de)
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Major pharmaceutical companies including Johnson & Johnson (NYSE: JNJ), Novartis AG (NYSE: NVS), Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. (NYSE: MRK), Eli Lilly & Co. (NYSE: LLY) and
![A Significant Reversal is in Sight for These 5 Med Tech Companies: https://www.marketbeat.com/logos/articles/med_20230829084134_chart-isrg-8292023ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWVCYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c9171d4803af83ef2057006fa40c8ba570850b84/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230829084134_chart-isrg-8292023ver001.png?locale=de)
A Significant Reversal is in Sight for These 5 Med Tech Companies
Med tech has been on the skids for no fault of its own. It’s not the industry's fault that price action was driven to a frothy bubble by COVID-inspired trading outlooks or that the market has
![5 Good Reasons it's Time to Buy High-Yield Dividend King 3M: https://www.marketbeat.com/logos/articles/med_20230829072150_chart-mmm-8292023ver001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2VBYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9deebd8e6e3b08758d0dc878c3b41e916831db7e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230829072150_chart-mmm-8292023ver001.png?locale=de)
5 Good Reasons it's Time to Buy High-Yield Dividend King 3M
3M (NYSE: MMM) is an interesting speculation on high-yield dividend growth and value, and now is an excellent time to take a bite. The company is navigating a difficult time with aplomb, and the
![Eilt: Biotech Hot Stock entwickelt Blockbuster - Hautkrebs vollständig geheilt. Jetzt 240% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71772/AC-250823.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNDk5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c25f9d809e0edaf28fa931f33f2819004f552001/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-250823.001.png?locale=de)
Eilt: Biotech Hot Stock entwickelt Blockbuster - Hautkrebs vollständig geheilt. Jetzt 240% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Biotech Hot Stock entwickelt Blockbuster - Hautkrebs vollständig geheilt. 240% mit Biotech Aktientip nach 134.452%
25.08.23 08:02
London (www.aktiencheck.de, Anzeige)
![Eilt: Hautkrebs vollständig geheilt - Biotech Hot Stock meldet Lizenzdeal mit Nr. 1. Jetzt 223% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71757/ac08-24-23-0ac01.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFI4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--77ca4a3590e303482f281ba86da50c36d1755764/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ac08-24-23-0ac01.001.png?locale=de)
Eilt: Hautkrebs vollständig geheilt - Biotech Hot Stock meldet Lizenzdeal mit Nr. 1. Jetzt 223% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Hautkrebs vollständig geheilt - Biotech Hot Stock meldet Lizenzdeal mit Nr. 1. 223% mit Biotech-Aktie nach 15.973%
24.08.23 08:03
London (www.aktiencheck.de, Anzeige)
![2 Stocks that Historically Rise in the Fall: https://www.marketbeat.com/logos/articles/med_20230820122334_chart-unh2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFo3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--774cde4835aa2cb1e1d0b9ccb9e28b1648b00cb4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230820122334_chart-unh2.jpg?locale=de)
2 Stocks that Historically Rise in the Fall
The start of school means that autumn is just around the corner. As temperatures drop, certain seasonal factors come into play in the country and specific industries. The stock market is a
![Eilt: Sensationeller Lizenzdeal mit Nr 1 - Hautkrebs vollständig geheilt. Jetzt 214% mit dieser Biotech-Aktie nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71744/Aktiencheck230823.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWg2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8039cd81269ed5e53c755b94a164e0b116970eee/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck230823.001.png?locale=de)
Eilt: Sensationeller Lizenzdeal mit Nr 1 - Hautkrebs vollständig geheilt. Jetzt 214% mit dieser Biotech-Aktie nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Sensationeller Lizenzdeal mit Nr. 1 - Hautkrebs vollständig geheilt. Neuer Biotech Aktientip nach 31205% mit Amgen
23.08.23
London (www.aktiencheck.de, Anzeige)
![Eilt: Lizenzdeal mit Nr. 1 in Israel - Hautkrebs vollständig geheilt. Neuer 212% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71731/ac08-22-23-ac01.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1Y1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--23e7161c79fc14db226e2998962c81f59f9ea9e7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ac08-22-23-ac01.001.png?locale=de)
Eilt: Lizenzdeal mit Nr. 1 in Israel - Hautkrebs vollständig geheilt. Neuer 212% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Lizenzdeal mit Nr. 1 in Israel - Hautkrebs vollständig geheilt. Neuer Biotech Hot Stock nach 134.452% mit Biogen
22.08.23 08:02
London (www.aktiencheck.de, Anzeige)